Veltkamp M, Drent M, Baughman RP. Infliximab or biosimilars in sarcoidosis; to switch or not to switch?. Sarcoidosis VDLD [Internet]. 2016 Jan. 15 [cited 2022 Jan. 27];32(4):280-3. Available from: https://www.mattioli1885journals.com/index.php/sarcoidosis/article/view/5001
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.